NorthWest Biotherapeutics Inc (NWBO)

[gnawkz]

Hey Pyrr, questions:

1. Are the DCs for DCVax-L not already matured when injected into the body? I thought only DCVax-D is partially matured upon injection.

2. Is there a difference between partial maturity and immaturity? Previous communications from the company indicate there is a substantial difference. Have you found research to suggest otherwise?

3. The immaturity referenced in the case studies that you've shared, are those immature DCs or already on their pathway to maturation?

4. Is the type of cancer important here? GBM vs Melanoma?

5. Is the size of the tumor an important factor here? The studies you've shared are for Melanoma, a type of cancer that can grow to be of a substantial size. For GBM, since space is limited, it cannot grow beyond a certain size. Is it logical to correlate the size of the tumor with the effectiveness of the immunosuppressive environment? (Larger tumor = stronger immunosuppressive environment.)

6. In addition, if the size of the tumor is minimal, would the number of DCs needed to migrate to the lymph node be smaller for there to be a clinical benefit?

Thanks in advance for the research.